Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway

Introduction: Osimertinib is a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of acquired resistance due to the EGFR-Del19/T790M/C797S mutation limits the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jingjing, Hao, Shaoyu, Liu, Xiantao, Li, Yingying, Zheng, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892466/
https://www.ncbi.nlm.nih.gov/pubmed/36744262
http://dx.doi.org/10.3389/fphar.2023.1093017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892466/
https://www.ncbi.nlm.nih.gov/pubmed/36744262
http://dx.doi.org/10.3389/fphar.2023.1093017

Ejemplares similares